EGFR p.E709_T710delinsD mutation may present with primary resistance and rapid progression on afatinib
Specific Lung Cancer Mutation May Lead to Rapid Treatment Failure
This case report and literature review describes a patient with stage IV lung adenocarcinoma and an EGFR p.E709_T710delinsD mutation who exp…
A specific mutation in lung cancer may cause patients to progress quickly on afatinib, highlighting the need for early monitoring and testin…
Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer
Toripalimab Treatment Linked to Heart and Muscle Inflammation
This case report and literature review describes a 74-year-old male with stage IIIA lung squamous cell carcinoma who developed multiple immu…
A single case study shows a patient with lung cancer developed heart and muscle inflammation after receiving toripalimab treatment.
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm
Icotinib Treatment for Lung Cancer Linked to Rare Blood Condition
This case report and literature review describes a 75-year-old female with lung adenocarcinoma treated with icotinib. The report identifies …
A rare case of acute myeloid leukemia was linked to a specific lung cancer treatment, highlighting the need for regular blood monitoring.
NLRP3 signaling and IL-1β inhibition show context-dependent roles in non-small cell lung cancer
IL-1β Inhibition Shows Potential in Non-Small Cell Lung Cancer
This narrative review synthesizes experimental and clinical data regarding NLRP3 signaling and IL-1β inhibition in non-small cell lung cance…
New research explores how blocking specific inflammatory pathways might influence the environment of non-small cell lung cancer.
First-line EGFR inhibitor options for advanced NSCLC require balancing efficacy with patient-centered tolerability trade-offs
New Treatment Options for Lung Cancer Patients with EGFR Mutations
This narrative review examines first-line therapy options for patients with advanced EGFR-mutated non-small cell lung cancer. The authors co…
Newer first-line therapies for lung cancer offer more options, but doctors must balance the strength of the drug against how well a patient …
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
PD-1/PD-L1 inhibitors with SRS or FSRT achieve 87% one-year local control in brain metastases
Combining immunotherapy and radiation for brain metastases shows promise
This meta-analysis of 2587 patients with brain metastases evaluated the combination of PD-1/PD-L1 inhibitors with stereotactic radiosurgery …
A new analysis shows that combining specific immunotherapy drugs with radiation can help control brain tumors and manage side effects.
TCM combined with EGFR-TKIs significantly improves progression-free survival in advanced EGFR-mutant NSCLC
Traditional Chinese medicine may improve survival for certain lung cancers
This meta-analysis evaluates the impact of traditional Chinese medicine (TCM) combined with EGFR-TKIs in patients with advanced EGFR-mutant …
Combining traditional Chinese medicine with targeted therapies may help patients with a specific type of lung cancer live longer without the…
mRNA vaccines provide a clinically validated platform to induce durable anti-tumor immunity in solid tumors
mRNA Vaccines Show Potential for Treating Several Solid Tumors
This systematic review evaluates mRNA vaccines for melanoma, pancreatic cancer, and non-small cell lung cancer. The authors conclude that mR…
mRNA technology is being used to create cancer vaccines that may help patients with melanoma, pancreatic, and lung cancers by building lasti…
Antibody-drug conjugates are expanding from late-line to first-line combination regimens in lung cancer
New Drug Class Shifts Lung Cancer Treatment Toward First-Line Use
This narrative review examines the expanding role of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and small cell lu…
A new class of cancer drugs is moving from last-resort treatment to first-line therapy for lung cancer, but early data need confirmation.
Atezolizumab with SBRT fails to improve survival in early NSCLC
Trial shows atezolizumab plus SBRT does not improve lung cancer survival
Adding atezolizumab to stereotactic body radiotherapy did not improve overall survival in inoperable early-stage NSCLC, while increasing sev…
A large phase 3 trial found that adding the immunotherapy drug atezolizumab to SBRT did not improve survival for patients with inoperable lu…
Polygenic methylation patterns are linked to osimertinib resistance in non-small cell lung cancer
Methylation Patterns Linked to Drug Resistance in Lung Cancer
This systematic review examines the role of polygenic DNA and RNA methylation in osimertinib resistance for patients with non-small cell lun…
New research identifies how changes in DNA and RNA methylation may contribute to drug resistance in patients with non-small cell lung cancer…
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Pembrolizumab-induced hypophysitis can cause arginine vasopressin deficiency unmasked by glucocorticoid therapy
Pembrolizumab Treatment Linked to Rare Hormone Deficiency in Lung Cancer
This case report and review describes a patient with metastatic lung adenocarcinoma who developed hypophysitis after pembrolizumab monothera…
A rare case of lung cancer treatment revealed a complex hormone deficiency that only appeared after the patient received steroid therapy.
Serplulimab induced grade 4 checkpoint inhibitor pneumonitis in an elderly patient with SCLC and COPD
New cancer treatment causes severe lung inflammation in elderly patients
This case report describes a grade 4 serplulimab-induced checkpoint inhibitor pneumonitis in an 80-year-old man with extensive-stage small c…
A new cancer drug caused severe, life-threatening lung inflammation in an 80-year-old man with existing lung disease.
Later-line antibody-drug conjugates show 25.7% objective response rate in advanced small-cell lung cancer
Antibody-drug conjugates show activity in advanced small-cell lung cancer
This systematic review and meta-analysis evaluates later-line monotherapy with antibody-drug conjugates (ADCs) for advanced small-cell lung …
Antibody-drug conjugates show promise for treating advanced small-cell lung cancer, though they are associated with frequent clinical toxici…
Tarlatamab improves symptom and functional outcomes in extensive-stage small cell lung cancer
New trial shows tarlatamab improves symptoms for lung cancer patients
This Phase 3 randomized controlled trial of 509 adults with extensive-stage small cell lung cancer found that tarlatamab improved several pa…
A new trial shows tarlatamab helps patients with small cell lung cancer manage symptoms like coughing and chest pain better than standard ch…
Atezolizumab and lurbinectedin combinations show potential for superior progression-free survival in extensive-stage small cell lung cancer
New Drug Combos Show Promise for Aggressive Small Cell Lung Cancer
This Bayesian network meta-analysis of 18 regimens in treatment-nađve patients with extensive-stage small cell lung cancer suggests that ate…
A massive analysis of 8,945 patients points to two drug cocktails that may extend survival in extensive-stage small cell lung cancer.
Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypothetical
Gut Health Links May Influence Lung Cancer Treatment Paths
This narrative review with a systematic search examined 168 studies on the gut-lung axis in non-small-cell and small-cell lung cancer. Solub…
New research explores how the gut-lung axis and specific metabolites might play a role in managing lung cancer treatments.
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer
New Treatment Approach Shows Success for a Rare Type of Lung Cancer
This case report describes a 61-year-old man with high-grade thoracic malignancy who achieved a pathologic complete response and undetectabl…
A 61-year-old man with a rare lung cancer showed a complete response after receiving a specific mix of drugs and surgery.
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases
Understanding the Role of PGE2 Signaling in Brain Health and Cancer
This systematic review examines the role of PGE2 signaling across neurological, oncological, and metabolic conditions. The findings indicate…
New research shows how different parts of a single protein pathway can either protect your brain or help tumors grow.
Surfactant protein D serves as a prognostic marker and potential therapeutic agent in various cancers
Protein D shows promise in diagnosing and treating several cancers
This narrative review explores the role of Surfactant protein D (SP-D) across multiple malignancies, including lung adenocarcinoma and breas…
A specific protein called Surfactant protein D may help doctors identify lung cancer and fight cells in breast and leukemia cases.
B7-H3-targeted ADCs achieve 54% objective response rate in previously treated small cell lung cancer
B7-H3 Targeted Drugs Show Promise for Small Cell Lung Cancer
This systematic review and meta-analysis evaluates B7-H3-targeted antibody-drug conjugates for patients with previously treated small cell l…
New data suggests B7-H3 targeted therapies may offer higher response rates than standard treatments for patients with small cell lung cancer…
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival
This meta-analysis of 3,910 patients with extensive-stage small-cell lung cancer (ES-SCLC) found that first-line immune checkpoint inhibitor…
Combining immune checkpoint inhibitors with chemotherapy shows better survival rates for patients with extensive stage small cell lung cance…
Questions about Non-Small Cell Lung Cancer
Can morning timing of immune checkpoint infusions improve survival outcomes in metastatic non-small cell lung cancer patients?
Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear benefits.
Full answer →Does a phase III trial show sublobar resection is better than lobectomy for small peripheral non–small cell lung cancer?
Yes, a phase III trial (CALGB 140503) found sublobar resection noninferior to lobectomy for disease-free survival in small peripheral NSCLC ≤2 cm.
Full answer →How do bispecific antibodies and CAR T-cell therapy work for advanced non–small cell lung cancer?
Bispecific antibodies and CAR T-cell therapy are two immunotherapies being tested for advanced NSCLC; bispecific antibodies show more clinical progress, while CAR T faces challenges like toxicity and tumor trafficking.
Full answer →What does the research say about using chemotherapy versus immunotherapy for advanced Non-Small Cell Lung Cancer?
For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.
Full answer →How does high PD-L1 expression affect treatment choices for advanced Non-Small Cell Lung Cancer?
High PD-L1 expression (≥50%) often makes immunotherapy, such as pembrolizumab, a first-line option for advanced NSCLC, but other factors like mutations also guide treatment.
Full answer →Can you explain the global disparities in access to new therapies for advanced Non-Small Cell Lung Cancer?
Global disparities in access to new NSCLC therapies stem from differences in drug approval, cost, testing infrastructure, and healthcare system resources.
Full answer →Is camrelizumab associated with a higher risk of disease progression compared to pembrolizumab?
In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one real-world study.
Full answer →Does real-world data support using pembrolizumab for my advanced Non-Small Cell Lung Cancer?
Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of 21 months and 29% survival at 5 years.
Full answer →All Non-Small Cell Lung Cancer Articles
- EGFR p.E709_T710delinsD mutation may present with primary resistance and rapid progression on afatinib
- Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer
- Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm
- First-line EGFR inhibitor options for advanced NSCLC require balancing efficacy with patient-centered tolerability trade-offs
- NLRP3 signaling and IL-1β inhibition show context-dependent roles in non-small cell lung cancer
- miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
- PD-1/PD-L1 inhibitors with SRS or FSRT achieve 87% one-year local control in brain metastases
- TCM combined with EGFR-TKIs significantly improves progression-free survival in advanced EGFR-mutant NSCLC
- mRNA vaccines provide a clinically validated platform to induce durable anti-tumor immunity in solid tumors
- Antibody-drug conjugates are expanding from late-line to first-line combination regimens in lung cancer
- Atezolizumab with SBRT fails to improve survival in early NSCLC
- Polygenic methylation patterns are linked to osimertinib resistance in non-small cell lung cancer
- TMB and TILs show no clear association with second primary cancer in resected NSCLC
- Multifactorial mechanisms including drug efflux and metabolic reprogramming drive paclitaxel resistance in several solid tumors
- Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypothetical
- Ivonescimab Combined With Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
- Bispecific antibodies improve progression-free survival and overall survival in patients with solid tumors
- Osimertinib plus chemotherapy improves progression-free survival by 18.4 months in TP53 and EGFR-mutated NSCLC
- Evaluating Chemoimmunotherapy versus Monotherapy for Advanced NSCLC Patients with High PD-L1 Expression
- EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastases
- Robotic-assisted thoracoscopic segmentectomy results in lower intraoperative blood loss compared to video-assisted thoracoscopic segmentectomy
- Durvalumab plus tremelimumab shows no significant overall survival benefit compared to durvalumab alone
- iPSC-derived CAR-NK extracellular vesicles represent a translational hypothesis for non-small cell lung cancer
- Metabolic parameters MTV and TLG predict poorer survival in NSCLC patients on immune checkpoint inhibitors
- Traditional Chinese medicine injections combined with chemotherapy may improve outcomes and tolerability in advanced NSCLC
- Sunvozertinib improves progression-free survival in patients with advanced NSCLC and EGFR exon 20 mutations
- Non-intubated VATS shows lower hazard for OS and DFS/RFS compared with intubated VATS
- Mefatinib improves median IRC-assessed progression-free survival to 13.7 months versus 9.7 months for gefitinib
- Advanced-stage NSCLC patients show higher objective response rates than early-stage patients on EGFR-TKI monotherapy
- Chemotherapy plus traditional Chinese medicine improves progression-free survival in advanced non-small cell lung cancer
- Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits
- Ivonescimab plus chemotherapy improves overall survival in patients with EGFR-variant nonsquamous NSCLC
- Lower baseline soluble PD-L1 levels correlate with improved progression-free and overall survival in NSCLC
- Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
- Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
- Robotic-assisted thoracoscopic segmentectomy increases lymph node stations examined and reduces hospital stay duration
- Ensartinib improves 24-month disease-free survival to 86.4% in resected ALK-positive NSCLC
- PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
- TROP2-targeting ADCs achieve 50.6% ORR in EGFR-mutant NSCLC following tyrosine kinase inhibitor failure
- Primary and acquired resistance to immune checkpoint inhibitors in NSCLC involves antigen presentation and TME remodeling
- Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
- Single-cell and spatial omics provide detailed mapping of tumor-immune ecosystems in non-small cell lung cancer
- Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
- Nivolumab plus chemotherapy improves pathological complete response in resectable NSCLC with PD-L1 < 1%
- Sublobar resection associated with improved overall survival compared to SBRT in early-stage non-small cell lung cancer
- Osimertinib treatment for EGFR-mutated NSCLC results in hypertension as the most common CVAE
- Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
- ALK tyrosine kinase inhibitors achieve 58.5% objective response rate in ALK-positive non-small cell lung cancer
- Intrathecal chemotherapy provides objective response rates of 34.5% to 86.4% in non-small-cell lung cancer leptomeningeal metastasis
- Sacituzumab Tirumotecan Combined With Pembrolizumab Improves Outcomes in PD-L1 Positive NSCLC
- High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
- CRT plus EGFR-TKI improves overall survival while EGFR-TKI plus RT ranks first for progression-free survival
- Statin use and EGFR-TKI efficacy in EGFR-mutant non-small cell lung cancer remains to be evaluated
- Fissios App plus physiotherapy aims to cut postoperative complications in NSCLC surgery
- Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
- OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
- Meta-analysis shows sublobar resection linked to worse survival outcomes compared with lobectomy for early-stage non-small cell lung cancer patients
- Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
- Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
- Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
- Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
- Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
- Perspective review on radiation therapy and cardiac toxicity in lung cancer
- Review of Non-small cell lung cancer without reported intervention or outcomes
- Systematic review and meta-analysis on neoadjuvant chemoimmunotherapy for resectable NSCLC
- Meta-analysis links emotional distress to worse outcomes in advanced lung cancer
- Systematic review and meta-analysis links higher prognostic nutritional index to better survival in non-small cell lung cancer
- Systematic review of intrathecal therapy for leptomeningeal metastasis in non-small cell lung cancer
- Morning immune checkpoint inhibitor infusions associated with improved survival in metastatic non-small-cell lung cancer
- Meta-analysis of PET/CT metabolic parameters for predicting NSCLC response after neoadjuvant therapy
- FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
- Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1
- Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer
- Post hoc reanalysis suggests stereotactic radiotherapy may improve local control in medically inoperable Stage I non-small cell lung cancer
- Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
- Narrative review explores Vaccinia virus therapy for non-small cell lung cancer with noted delivery challenges
- FDA Approves Lazcluze (lazertinib) with Amivantamab for EGFR-Mutant NSCLC
- Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
- Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
- Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
- RNK08954 shows unconfirmed responses in KRASG12D-mutant NSCLC and PDAC in Phase Ia trial
- Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients
- Combination therapy shows promising progression-free survival in advanced non-small cell lung cancer patients with high PD-L1 expression
- Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
- Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
- High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
- CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
- Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
- Narrative review discusses tumor draining lymph nodes as a target for NSCLC therapy
- CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
- Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
- Review of 68Ga-Pentixafor PET/CT Utility in Lung Cancer Diagnosis and Management
- Narrative review examines abscopal effect potential in non-small cell lung cancer multimodality therapies
- Preoperative inflammatory markers linked to survival in resectable NSCLC
- Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
- Narrative review summarizes bispecific antibodies and CAR T-cell therapy for advanced lung cancer
- Meta-analysis shows local consolidative therapy plus systemic therapy improves survival in driver-negative oligometastatic NSCLC
- Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
- Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
- Mini-review of phase III trial data on sublobar resection for small peripheral NSCLC
- Combined radiomics classifier predicts 3-year recurrence in surgically resected stage IA-IIIA non-small cell lung cancer
- HS-20093 shows response in lung cancers in Phase 1a/b trial
- Meta-analysis shows KRASG12C inhibitors improve outcomes versus chemotherapy in KRAS-mutant NSCLC
- Izalontamab brengitecan shows activity in pretreated NSCLC with non-classical actionable genomic alterations
- SABR shows 46% 5-year overall survival in unfit NSCLC patients in phase 2 trial
- Setidegrasib shows antitumor activity in advanced NSCLC and pancreatic cancer with p.G12D variants
- First-line platinum-based chemotherapy associated with disease control and survival in recurrent NSCLC patients
- Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
- First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases
- Concurrent TP53 and KRAS alterations show inconsistent survival impact across gastrointestinal cancers
- In Appalachian lung cancer patients, definitive chemoradiotherapy was associated with a 59% incidence of cardiovascular adverse events
- Meta-analysis shows radiomics-based machine learning models predict recurrence risk in non-small cell lung cancer patients
- AI-based PD-L1 scoring shows concordance with expert assessment in 333 NSCLC cases
- PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
- Eight-week mindfulness-based stress reduction reduced fatigue, anxiety, and depression in non-small cell lung cancer patients
- SBRT shows early QoL advantage over CHRT in inoperable stage I NSCLC, but long-term scores converge
- Firmonertinib plus anlotinib shows preliminary efficacy in advanced EGFR-mutant NSCLC
- Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
- BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
- Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
- Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases
- Fulzerasib plus cetuximab shows 69% response in first-line KRAS-mutated NSCLC
- Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
- Global disparities persist in access to molecular diagnostics and novel therapies for advanced NSCLC
- Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
- Perioperative tislelizumab plus chemotherapy improves survival in Chinese patients with resectable NSCLC
- Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
- Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results
- Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
- VATS lobectomy improves overall survival vs open surgery in early-stage NSCLC
- Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
- Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients